drugset / Trial / NCT04836858
A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of this phase 2 study was to assess the efficacy and safety of CMK389 in patients with atopic dermatitis.
Timeline
- Start
- 2021-04-20
- Primary completion
- 2022-07-14
- Completion
- 2022-12-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CMK389 | Unknown | 10 mg/kg | Intravenous |
| Subject | CMK389 | Unknown | 300 mg | Intravenous |